Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-08-07
2007-08-07
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S524000
Reexamination Certificate
active
10827616
ABSTRACT:
The invention relates to novel CD1a-presented antigens. These antigens can be used as antigens, adjuvants or as immunomodulatory agents in a variety of diagnostic, therapeutic and prophylactic applications.
REFERENCES:
patent: 5538733 (1996-07-01), Emery et al.
patent: 5679347 (1997-10-01), Porcelli et al.
patent: 5853737 (1998-12-01), Modlin et al.
patent: 6063919 (2000-05-01), Gaudioso et al.
patent: 6238676 (2001-05-01), Porcelli et al.
patent: 6310058 (2001-10-01), Miller et al.
patent: 2002/0009465 (2002-01-01), Porcelli et al.
patent: 2003/0206914 (2003-11-01), Porcelli et al.
patent: WO 95/00163 (1995-01-01), None
patent: WO 96/12190 (1996-04-01), None
patent: WO 99/12562 (1999-03-01), None
patent: WO 99/52547 (1999-10-01), None
patent: WO 03/013596 (2003-02-01), None
Tsukamoto et al. (Journal of Antibiotics (1997), 50(10), 815-821).
Ikeda-Fujita, T. et al., “Antitimor Effects of a Novel Immunomodulator Holding Many Bioactivitiesw in Common With Endotoxins Derived From Mycobacteriam-Bovis BCG”,Japanese J. of Bacteriology, vol. 42(6), pp. 851-856, 1987.
Adilakshmi et al., Mutational analysis of a role for salicylic acid in iron metabolism ofMycobacterium smegmatis. J Bacteriol. Jan. 2000;182(2):264-71.
Bosne-David et al., Evaluation of growth promotion and inhibition from mycobactins and nonmycobacterial siderophores (Desferrioxamine and FR160) inMycobacterium aurum. Antimicrob Agents Chemother. Aug. 1997;41(8):1837-9.
Cui et al., Requirement for Valpha 14 NKT cells in IL-12-mediated rejection of tumors. Science. Nov. 28, 1997;278(5343):1623-6.
DeVoss et al., The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc Natl Acad Sci U S A. Feb. 1, 2000;97(3):1252-7.
Dussurget et al., An ideR mutant ofMycobacterium smegamatishas derepressed siderophore production and an altered oxidative-stress response. Mol Microbiol. Nov. 1996;22(3):535-44. Abstract Only.
Fiss et al., Identification of genes involved in the sequestration of iron in mycobacteria: the ferric exochelin biosynthetic and uptake pathways. Mol Microbiol. Nov. 1994;14(3):557-69. Abstract Only.
Gobin et al., Exochelins ofMycobacterium tuberculosisremove iron from human iron-binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall. J Exp Med. Apr. 1, 1996;183(4):1527-32.
Gobin et al., Iron acquisition byMycobacterium tuberculosis: isolation and characterizationi of a family of iron-binding exochelins. Proc Natl Acad Sci U S A. May 23, 1995;92(11):5189-93.
Lambrecht et al., Inability to detect mycobactin in mycobacteria-infected tissues suggests an alternative iron acquisition mechanism by mycobacteria in vivo. Microb Pathog. Mar. 1993;14(3):229-38. Abstract Only.
Lin et al., The remarkable hydrophobic effect of a fatty acid side chain on the mirobial growth promoting activity of synthetic siderophore. Biometals. Jun. 2001;14(2):153-7. Abstract only.
Matzanke et al., Iron uptake and intracellular metal transfer in mycobacteria mediated by xenosiderophores. Biometals. Jul. 1997;10(3):193-203. Abstract Only.
Messenger et al., Iron uptake processes in Mycobacterium vaccae R877R, a mycobacterium lacking mycobactin. J Gen Microbiol. Mar. 1986;132 (Pt 3):845-52. Abstract Only.
Moody et al., T cell activation by lipopeptide antigens. Science. Jan. 23, 2004;303(5657):527-31.
Moody Cliffe et al., Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol. Dec. 2000;1(6):521-5.
Nieuwenhuis et al., CD1d-dependent macrophage-mediated clearance ofPseudomonas aeruginosafrom lung. Nat Med. Jun. 2002;8(6):588-93.
Quadri et al., Identification of aMycobacterium tuberculosisgene cluster encoding the biosynthetic enzymes for assembly of the virulence-conferrring siderophore mycobactin. Chem Biol. Nov. 1998;5(11):631-45.
Raghu et al., Effect of anti-tuberculosis drugs on the iron-sequestration mechanisms of mycobacteria. Indian J Pathol Microbiol. Jul. 1995;38(3):287-92. Abstract Only.
Raghu et al., Effect of iron on the growth and siderophore production of mycobacteria. Biochem Mol Biol Int. Oct. 1993;31(2):341-8. Abstract Only.
Raghu et al., Isolation and characterization of siderophores and envelope proteins from mycobacteria. Biochem Mol Biol Int. Oct. 1993;31(2):333-9. Abstract Only.
Raghu et al., Effect of hemoglobin on the growth of mycobacteria and the production of siderophores. Indian J Pathol Microbiol. Oct. 1993;36(4):376-82. Abstract Only.
Ratledge et al., The occurrence of carboxymycobactin, the siderophore of pathogenic mycobacteria, as a second extracellular siderophore inMycobacterium smegmatis. Microbiology. Aug. 1996;142 (Pt 8):2207-12. Abstract Only.
Rosat et al., CD1-restricted microbial lipid antigen-specific recognition found in the CD8+ alpha beta T cell pool. J Immunol. Jan. 1, 1999;162(1):366-71.
Scheibel et al., Antimalarial activity of selected aromatic chelators. IV. Cation uptake by Plasmodium falciparum in the presence of oxines and siderochromes. Mol Pharmacol. Oct. 1986;30(4):364-9. Abstract Only.
Schumann et al., Screening system for xenosiderophores as potential drug delivery agents in mycobacteria. Antimicrob Agents Chemother. May 2001;45(5):1317-22.
Snow et al., Metal complexes of mycobactin P and of desferrisideramines. Biochem J. Nov. 1969;115(2):199-205.
Stenger et al., Differential effects of cytolytic T cell subsets on intracellular infection. Science. Jun. 13, 1997;276(5319):1684-7.
Szarapinska-Kwaszewska et al., [Utilization of siderophores from mycobacteria byStaphylococcus] Med Dosw Mikrobiol. 1998;50(3-4):239-49. Polish.
Terabe et al., NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol. Dec. 2000;1(6):515-20.
Zhu et al., Exochelin genes inMycobacterium smegmatis: identification of an ABC transporter and two non-ribosomal peptide synthetase genes. Mol Microbiol. Jul. 1998;29(2):629-39.
Vergne et al., Iron chelators from mycobacteria (1954-1999) and potential therapeutic applications,Nat. Prod. Rep., 2000, 17:99-116.
Costello Catherine E.
Moody D. Branch
Young David C.
Kifle Bruck
The Brigham and Women's Hospital, Inc.
Trustees of Boston University
Wolf Greenfield & Sacks P.C.
LandOfFree
Methods and compositions for immunomodulation using CD1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for immunomodulation using CD1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for immunomodulation using CD1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3888865